Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Acute Kidney Injury D058186 34 associated lipids
Airway Remodeling D056151 3 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Hypoalphalipoproteinemias D052456 5 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Cholecystitis, Acute D041881 1 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Stenosis D023921 6 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Stroke D020521 32 associated lipids
Latex Hypersensitivity D020315 1 associated lipids
Intracranial Hemorrhage, Hypertensive D020299 1 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Venous Thrombosis D020246 11 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Carotid Artery Injuries D020212 8 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Basal Ganglia Hemorrhage D020145 1 associated lipids
Thrombophilia D019851 6 associated lipids
Endotoxemia D019446 27 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Atrial Premature Complexes D018880 1 associated lipids
Sepsis D018805 11 associated lipids
Systemic Inflammatory Response Syndrome D018746 4 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Osteoblastoma D018215 1 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
beta-Thalassemia D017086 5 associated lipids
Carotid Stenosis D016893 15 associated lipids
Death, Sudden, Cardiac D016757 12 associated lipids
Yang Deficiency D016711 3 associated lipids
Diabetes, Gestational D016640 8 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Peripheral Vascular Diseases D016491 8 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacteremia D016470 9 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Myocardial Reperfusion Injury D015428 20 associated lipids
Reperfusion Injury D015427 65 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Wounds and Injuries D014947 20 associated lipids
Weil Disease D014895 2 associated lipids
Granulomatosis with Polyangiitis D014890 5 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Yoshino T et al. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor. 2005 Arzneimittelforschung pmid:16080279
Mancini F et al. Time since menopause does not affect plasma viscosity, plasma thromboxane levels and Doppler findings. 2005 Gynecol. Endocrinol. pmid:16019357
Mancini F et al. Effects of hormone replacement therapy on plasma viscosity and Doppler variations in postmenopausal non-smokers and heavy smokers. 2005 Gynecol. Endocrinol. pmid:16019365
Michibayashi T Platelet aggregation and vasoconstriction related to platelet cyclooxygenase and 12-lipoxygenase pathways. 2005 J. Atheroscler. Thromb. pmid:16020916
Svenstrup Poulsen T et al. A critical appraisal of the phenomenon of aspirin resistance. 2005 Cardiology pmid:16020925
Walsh DS et al. Characterization of circulating monocytes expressing HLA-DR or CD71 and related soluble factors for 2 weeks after severe, non-thermal injury. 2005 J. Surg. Res. pmid:16045935
Rodrigue ME et al. Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats. 2005 Can. J. Physiol. Pharmacol. pmid:16049546
Montuschi P et al. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. 2005 Thorax pmid:16192367
Hsiao G et al. alpha-Naphthoflavone, a potent antiplatelet flavonoid, is mediated through inhibition of phospholipase C activity and stimulation of cyclic GMP formation. 2005 J. Agric. Food Chem. pmid:15969494
Munsterhjelm E et al. Characterization of inhibition of platelet function by paracetamol and its interaction with diclofenac in vitro. 2005 Acta Anaesthesiol Scand pmid:15954969
Vangroenweghe F et al. Effect of carprofen treatment following experimentally induced Escherichia coli mastitis in primiparous cows. 2005 J. Dairy Sci. pmid:15956299
Wakamoto S et al. Effects of hemoglobin vesicles on resting and agonist-stimulated human platelets in vitro. 2005 Artif Cells Blood Substit Immobil Biotechnol pmid:15960075
Al Kadi H et al. A prospective, longitudinal study of the renin-angiotensin system, prostacyclin and thromboxane in the first trimester of normal human pregnancy: association with birthweight. 2005 Hum. Reprod. pmid:16006463
Beretta C et al. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. 2005 Pharmacol. Res. pmid:15939622
Visioli F et al. Virgin Olive Oil Study (VOLOS): vasoprotective potential of extra virgin olive oil in mildly dyslipidemic patients. 2005 Eur J Nutr pmid:15309433
Jin YR et al. Antiplatelet activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization. 2005 J. Pharmacol. Exp. Ther. pmid:15328379
Jin YR et al. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets. 2005 Basic Clin. Pharmacol. Toxicol. pmid:16128910
Jermany J et al. Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects. 2005 J Clin Pharmacol pmid:16172182
Persico N et al. Transdermal HRT and Doppler findings in normotensive and hypertensive postmenopausal patients. 2005 Ultrasound Obstet Gynecol pmid:16184506
Perini JA et al. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. 2005 Clin. Pharmacol. Ther. pmid:16198655
Davì G et al. Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. 2005 Arterioscler. Thromb. Vasc. Biol. pmid:15472127
Maree AO et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. 2005 J. Am. Coll. Cardiol. pmid:16198840
Saloheimo P et al. Thromboxane and prostacyclin biosynthesis in patients with acute spontaneous intracerebral hemorrhage. 2005 Thromb. Res. pmid:15733969
Trebino CE et al. Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages. 2005 J. Biol. Chem. pmid:15722356
García-Saura MF et al. Effects of chronic quercetin treatment in experimental renovascular hypertension. 2005 Mol. Cell. Biochem. pmid:15792364
Awad AS et al. Increased renal production of angiotensin II and thromboxane B2 in conscious diabetic rats. 2005 Am. J. Hypertens. pmid:15831366
De Candia E et al. Abnormal pH-sensing of platelet Na+/H+ exchanger in patients with cardiac syndrome X. 2005 Int. J. Cardiol. pmid:15837078
Capone ML et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. 2005 J. Am. Coll. Cardiol. pmid:15837265
Oliveira RL et al. Postmenopausal hormone replacement therapy increases plasmatic thromboxane beta 2. 2005 Int. J. Cardiol. pmid:15771927
Cryer B et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. 2005 Clin Ther pmid:15811481
Chang Y et al. Mechanisms involved in the antiplatelet activity of ketamine in human platelets. 2004 Nov-Dec J. Biomed. Sci. pmid:15591773
Barrière G et al. PHGPx overexpression induces an increase in COX-2 activity in colon carcinoma cells. 2004 May-Jun Anticancer Res. pmid:15274299
Böhm E et al. 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. 2004 J. Biol. Chem. pmid:14668348
Kudolo GB et al. The ingestion of Ginkgo biloba extract (EGb 761) inhibits arachidonic acid-mediated platelet aggregation and thromboxane B2 production in healthy volunteers. 2004 J Herb Pharmacother pmid:15927922
Moriguchi A et al. Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban. 2004 J. Pharmacol. Exp. Ther. pmid:14634048
Valeri CR et al. In vitro effects of poly-N-acetyl glucosamine on the activation of platelets in platelet-rich plasma with and without red blood cells. 2004 J Trauma pmid:15280746
Singer P and Wirth M Can n-3 PUFA reduce cardiac arrhythmias? Results of a clinical trial. 2004 Prostaglandins Leukot. Essent. Fatty Acids pmid:15253884
Barbieri SS et al. Apocynin prevents cyclooxygenase 2 expression in human monocytes through NADPH oxidase and glutathione redox-dependent mechanisms. 2004 Free Radic. Biol. Med. pmid:15203187
Kojima F et al. Membrane-associated prostaglandin E synthase-1 is upregulated by proinflammatory cytokines in chondrocytes from patients with osteoarthritis. 2004 Arthritis Res. Ther. pmid:15225371
de La Puerta Vázquez R et al. Effects of different dietary oils on inflammatory mediator generation and fatty acid composition in rat neutrophils. 2004 Metab. Clin. Exp. pmid:14681843
von Aulock S et al. Granulocyte colony-stimulating factor (filgrastim) treatment primes for increased ex vivo inducible prostanoid release. 2004 J. Pharmacol. Exp. Ther. pmid:14610236
Minuz P et al. Determinants of platelet activation in human essential hypertension. 2004 Hypertension pmid:14656953
Liu P et al. [Effects of the extracts from decoction for resuscitation and its component herbs on PGI2, TXA2 and NO release from rat vascular endothelial cells under hypoxia in vitro]. 2004 Zhongguo Zhong Yao Za Zhi pmid:15631091
Yang JP et al. [Changes of the platelet function and serum anticardiolipin antibody in patients with pulmonary thromboembolism]. 2004 Zhonghua Jie He He Hu Xi Za Zhi pmid:15634381
Wang MS et al. [The effects of lupus anticoagulant on pulmonary thromboembolism]. 2004 Zhonghua Jie He He Hu Xi Za Zhi pmid:15634384
Díaz AM et al. Phenylpropanoid glycosides from Scrophularia scorodonia: in vitro anti-inflammatory activity. 2004 Life Sci. pmid:15010262
Rotondo S et al. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. 2004 Eur. J. Pharmacol. pmid:15044038
Guay J et al. Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1. 2004 J. Biol. Chem. pmid:15044444
Véricel E et al. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. 2004 Diabetes pmid:15047620
Yugar-Toledo JC et al. Uncontrolled hypertension, uncompensated type II diabetes, and smoking have different patterns of vascular dysfunction. 2004 Chest pmid:15006938